AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21945866
Drug: lipid control,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lipid control, LC (15 g non‐emulsified lipid/water, containing 4.2g lipid, 0.2 MJ)+water
Trial: 20414715
Drug: Modular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modular treatment in clinic settings
Trial: 20414715
Drug: Modular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modular treatment in community settings
Trial: 11943438
Drug: Antiretroviral drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral drug A
Trial: 11943438
Drug: Antiretroviral drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral drug B
Trial: 8602629
Drug: GM‐CSF 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM‐CSF 250 microg/m2 subcutaneously every 12 hr after each course of DICEP until recovery of ANC of 1.5 x 10(9)/L
Trial: 8602629
Drug: Placebo subcutaneously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo subcutaneously every 12 hr after each course of DICEP until recovery of ANC of 1.5 x 10(9)/L
Trial: 1761663
Drug: Delayed administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delayed administration of human chorionic gonadotrophin (HCG) by 24 hours in 96 patients.
Trial: 1761663
Drug: Standard administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard administration of human chorionic gonadotrophin (HCG) in 47 patients when the three largest follicles were >= 17 mm.
Trial: 7080505
Drug: Hexoprenaline (beta‐2‐selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexoprenaline (beta‐2‐selective bronchodilator) in paediatric syrup form, dosage not specified, duration not specified
Trial: 31823222
Drug: Dupilumab 200
RxNorm normalized name: dupilumab 200 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 200 or 300 mg every 2 weeks (q2w)
Trial: 25028506
Drug: Transdermal 4-hydroxytamoxifen
RxNorm normalized name: 4-hydroxytamoxifen
DrugBank: Afimoxifene (DB04468)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 4-hydroxytamoxifen gel (4-OHT) 4 mg/day
Trial: 25028506
Drug: Oral tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tamoxifen (oral-T) 20 mg/day
Trial: 25028506
Drug: Transdermal 4-hydroxytamoxifen
RxNorm normalized name: 4-hydroxytamoxifen
DrugBank: Afimoxifene (DB04468)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 4-hydroxytamoxifen gel (4-OHT)
Trial: 25028506
Drug: Oral tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tamoxifen (oral-T)
Trial: 22656335
Drug: Zinc (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc (10 mg orally daily)
Trial: 12817747
Drug: Hormone Replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone Replacement Therapy (HRT) with cyclic estrogen and progestogen (norethisterone acetate) for 2 years
Trial: 2188408
Drug: Terbutaline via
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline via freon spray (aerosol)
Trial: 27476110
Drug: Affect Regulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Affect Regulation Treatment to Enhance Methamphetamine Intervention Success (ARTEMIS)
Trial: 22415569
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg rosiglitazone daily for 12 weeks
Trial: 7577408
Drug: rhGH 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH 0.05 mg/kg per day subcutaneously
Trial: 2289216
Drug: Enalapril (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (up to 40 mg daily)
Trial: 2289216
Drug: Sustained-release diltiazem
RxNorm normalized name: diltiazem
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sustained-release diltiazem (360 mg daily)
Trial: 26038356
Drug: Ibandronate (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate (6 mg intravenous or 50 mg oral)
Trial: 21790680
Drug: Topical beclomethasone
RxNorm normalized name: beclomethasone Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical beclomethasone dipropionate (BDP) 3mg enema during radiotherapy and 2x3mg suppositories for 4 weeks
Trial: 21790680
Drug: Topical beclomethasone
RxNorm normalized name: beclomethasone Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical beclomethasone dipropionate (BDP)
Trial: 20175432
Drug: 6.4% CHO‐E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.4% CHO‐E solution
Trial: 10198297
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution (PLA)
Trial: 15024373
Drug: Chlorhexidine gluconate
RxNorm normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine gluconate (spray or swab)
Trial: 2499524
Drug: 1,000 mg
RxNorm normalized name: bran 1,000 mg ORAL WAFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg ibuprofen-lysinsalt
Trial: 30947740
Drug: Humidified high-flow
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humidified high-flow oxygenation via nasal cannula at 60 L/min
Trial: 30947740
Drug: Non-rebreather mask
RxNorm normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Non-rebreather mask and standard nasal cannula at an oxygen flow rate of 15 L/min
Trial: 25667281
Drug: Image-Guided Radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Image-Guided Radiation Therapy (IGRT)
Trial: 18266537
Drug: Non-aggression-focused behavioral
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-aggression-focused behavioral couple therapy
Trial: 16365124
Drug: Immediate weight-bearing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate weight-bearing mobilisation after conservative treatment
Trial: 14651538
Drug: Intravenous ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous ibuprofen lysine 10 mg/kg, followed by 5 mg/kg after 24 and 48 h (n = 32)
Trial: 14651538
Drug: Intravenous indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous indomethacin 0.2 mg/kg every 12 h for three doses (n = 31)
Trial: 6356902
Drug: Labetalol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (100 mg twice a day)
Trial: 6356902
Drug: Labetalol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (400 mg twice a day, maximum dose)
Trial: 8680787
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of recombinant tissue plasminogen activator (tPA) compounded in 1% hyaluronate acid (HA) at doses of 0.25, 0.5, and 1.0 mg/ml for 4 weeks
Trial: 28721886
Drug: Yoga intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Yoga intervention (twice-weekly classes during RT)
Trial: 16306923
Drug: Mediterranean diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mediterranean diet group (MG; n=48)
Trial: 8087579
Drug: Standardized therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized therapy via computerized protocols
Trial: 3815140
Drug: Cefazolin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin (1 g intravenous injections, four doses over 12 hours)
Trial: 3815140
Drug: Cefamandole (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefamandole (750 mg intravenous injections, four doses)
Trial: 15388432
Drug: Both antibiotics
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both antibiotics
Trial: 26027135
Drug: Supplementing Qi
RxNorm normalized name: San Qi Root
DrugBank: Panax notoginseng root (DB14304)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplementing Qi and activating blood circulation herbs (60 mL per time, 3 times a day for 14 days)
Trial: 10435606
Drug: Nalmefene (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalmefene (20 mg/d and 80 mg/d)
Trial: 7772078
Drug: Beta-carotene supplementation
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene supplementation (50-100 mg on alternate days for 3 weeks after a loading dose of 100 mg/day for 1 week)
Trial: 729618
Drug: Tiamenidine 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiamenidine 1.0 mg
Trial: 30995329
Drug: Midazolam with
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam with magnesium (2 g bolus at 30 minutes, 16 mg/24-hour magnesium infusion)
Trial: 30995329
Drug: Midazolam (0.03-0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.03-0.3 mg/kg bolus loading dose + 0.03-0.2 mg/kg/hour infusion)
Trial: 19727982
Drug: BPD-LL with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BPD-LL with high-calcium diet, 200 IU of vitamin D, and 100 mg elemental calcium daily
Trial: 19727982
Drug: BPD-LL with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BPD-LL with high-calcium diet, 200 IU of vitamin D, 100 mg elemental calcium daily, and an extra 2 g of calcium
Trial: 11176084
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl at a target plasma concentration of 2.5 ng/ml
Trial: 11176084
Drug: Epidural analgesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural analgesia using ropivacaine in combination with 2 microg/ml fentanyl
Trial: 9037222
Drug: Cortisol (perioperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol (perioperative injections)
Trial: 9037222
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (perioperative injections)
Trial: 22866937
Drug: Oat group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oat group (100 grams of instant oat cereal daily)
Trial: 22866937
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (100 grams of wheat flour-based noodles daily)
Trial: 21803569
Drug: Everolimus 10mg
RxNorm normalized name: EVEROLIMUS 10MG TAB
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus 10mg once daily
Trial: 26051564
Drug: Classical homeopathic
RxNorm normalized name: Urtica urens homeopathic preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classical homeopathic adjunctive therapy
Trial: 19349312
Drug: Corticotropin-releasing hormone
RxNorm normalized name: corticotropin-releasing hormone
DrugBank: Corticorelin (DB05394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticotropin-releasing hormone (CRH) 1 microg/kg intravenously
Trial: 16917445
Drug: Creatine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine administration (0.4 gr/kg daily for 6 months)
Trial: 9143434
Drug: Tacrine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrine treatment in patients with WMLA
Trial: 9143434
Drug: Tacrine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrine treatment in patients without WMLA
Trial: 7968872
Drug: Nifedipine or
RxNorm normalized name: nifedipine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine or nitrendipine (3 to 6 month treatment)
Trial: 3609121
Drug: Trimethoprim suspension
RxNorm normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trimethoprim suspension 3 mg/kg (fasting)
Trial: 3609121
Drug: Trimethoprim suspension
RxNorm normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trimethoprim suspension 3 mg/kg (with food)
Trial: 3609121
Drug: Trimethoprim suspension
RxNorm normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trimethoprim suspension 3 mg/kg (with food and guar)
Trial: 26582972
Drug: A‐GPC (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A‐GPC (600 mg per day)
Trial: 18495508
Drug: Alendronate 70mg
RxNorm normalized name: ALENDRONATE 70MG TAB
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate 70mg once weekly
Trial: 16626981
Drug: 1 mM
RxNorm normalized name: PhaSeal Protector, 21 mm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mM BMTd lotion applied twice daily for 14 days
Trial: 16626981
Drug: 1 mM
RxNorm normalized name: PhaSeal Protector, 21 mm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mM BMTd lotion applied twice daily for 2 weeks to one eye
Trial: 16626981
Drug: 2 mM
RxNorm normalized name: Adapta-Cap C 22 mm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mM BMTd lotion applied to lips
Trial: 10997370
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate (MA) 10 mg/kg/d
Trial: 1327697
Drug: Surgery plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery plus postoperative chemotherapy (SC)
Trial: 1327697
Drug: Preoperative radiotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative radiotherapy plus surgery followed by postoperative chemotherapy (RSC)
Trial: 3906516
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine sulfate (MS)
Trial: 30664397
Drug: Guided Physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided Physical Exercise and Dietary therapy (PED‐t)
Trial: 27452293
Drug: Calcium hydroxide
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium hydroxide medication
Trial: 21951980
Drug: Psychosocial treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychosocial treatment (up to 6 months)
Trial: 10102587
Drug: IAN block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IAN block + intraosseous injection of 1.8 mL of 2% mepivacaine with 1:20,000 levonordefrin
Trial: 10102587
Drug: IAN block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IAN block + intraosseous injection of 1.8 mL of 2% lidocaine with 1:100,000 epinephrine
Trial: 10102587
Drug: IAN block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IAN block + mock intraosseous injection
Trial: 10102587
Drug: Heart rate
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heart rate increase with intraosseous injection of mepivacaine and lidocaine
Trial: 2116260
Drug: Pravastatin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin monotherapy (5 mg, 10 mg, and 20 mg twice daily)
Trial: 2116260
Drug: Pravastatin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin with cholestyramine therapy
Trial: 31638882
Drug: Group Music
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Music Therapy (GMT) combined with Treatment as Usual (TAU)
Trial: 28625255
Drug: D3 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D3 treatment group (supplemented 300 kU vitamin D3)
Trial: 28625255
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (injected 1 mL physiological saline)
Trial: 28625255
Drug: D3 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D3 treatment group
Trial: 27352341
Drug: Continuous sedation
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous sedation therapy with midazolam
Trial: 22013734
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet (120 mg of starch)
Trial: 18036708
Drug: IMVAMUNE (MVA)
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMVAMUNE (MVA) vaccine administered at Study Days 0 and 28 by subcutaneous or intramuscular injection
Trial: 18036708
Drug: IMVAMUNE (MVA)
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMVAMUNE (MVA) vaccine
Trial: 15023585
Drug: Fluoxetine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine plus olanzapine (5-10 mg, mean 6.1 mg)
Trial: 14714042
Drug: Etanercept (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (25 mg twice per week subcutaneously)
Trial: 7880782
Drug: 0.006% latanoprost
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.006% latanoprost given twice daily
Trial: 26062190
Drug: Auricular point
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Auricular point sticking before operation combined with paracetamol and dihydrocodeine tartrate tablets, and diosmin tablets.
Trial: 26062190
Drug: Paracetamol and
RxNorm normalized name: Paracetamol and tramadol only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol and dihydrocodeine tartrate tablets, and diosmin tablets.
Trial: 21455007
Drug: Daily glycerin
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily glycerin suppository (250 mg for 24‐27(+6) weeks subgroup or 500 mg for 28‐31(+6) weeks subgroup) for 10 days from 24 hours of age
Trial: 21455007
Drug: Daily glycerin
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily glycerin suppository
Trial: 18507650
Drug: 8 g/l
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 g/l GOS/FOS in a 9 : 1 ratio (IMMUNOFORTIS)
Trial: 18507650
Drug: 8 g/l
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 g/l maltodextrine (placebo)
Trial: 17692729
Drug: Probiotic-prebiotic complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic-prebiotic complex treatment
Trial: 17692729
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (2 weeks after crossover to treatment)
Trial: 15051746
Drug: Ximelagatran +
RxNorm normalized name: XIMELAGATRAN
DrugBank: Ximelagatran (DB04898)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ximelagatran + Alcohol (0.5 g/kg for women, 0.6 g/kg for men)
Trial: 9924220
Drug: Hyperbaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric bupivacaine 5 mg ml‐1
Trial: 9924220
Drug: Isobaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isobaric bupivacaine 5 mg ml‐1
Trial: 7800402
Drug: Bupivacaine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (30 cc of 0.25% bupivacaine with 1:200,000 epinephrine)
Trial: 7800402
Drug: Morphine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (2 mg in 28 cc normal saline, total volume 30 cc)
Trial: 24963830
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy-based training intervention (ACTr)
Trial: 15130916
Drug: Hormone Replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone Replacement Therapy (HRT) (estrogen plus progestin)
Trial: 8379860
Drug: Iron dextran
RxNorm normalized name: Iron Dextran
DrugBank: Iron Dextran (DB00893)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron dextran injections (5 injections spaced 4 weeks)
Trial: 3093556
Drug: Cromolyn sodium
RxNorm normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cromolyn sodium 2 mg
Trial: 3093556
Drug: Cromolyn sodium
RxNorm normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cromolyn sodium 10 mg
Trial: 2932989
Drug: Cromolyn sodium
RxNorm normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cromolyn sodium 20 mg
Trial: 22233510
Drug: Op Volle
RxNorm normalized name: Schinus molle pollen
DrugBank: Schinus molle pollen (DB10483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Op Volle Kracht (OVK) intervention, consisting of 16 lessons of 50 min each, incorporating Cognitive Behavioral Therapy, social skills training, problem solving, and decision making.
Trial: 20579510
Drug: Extended-release fluvoxamine
RxNorm normalized name: fluvoxamine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release fluvoxamine (fluvoxamine ER) 100 mg/d, titrated to 100-300 mg/d
Trial: 20579510
Drug: Extended-release fluvoxamine
RxNorm normalized name: fluvoxamine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release fluvoxamine (fluvoxamine ER) during 40-week open-label extension
Trial: 16104906
Drug: Low-dose thalidomide
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose thalidomide (200 mg)